CGF166
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
Conditions
Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
Trial Timeline
Jun 23, 2014 → Dec 9, 2019
NCT ID
NCT02132130About CGF166
CGF166 is a phase 1/2 stage product being developed by Novartis for Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT02132130. Target conditions include Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02132130 | Phase 1/2 | Completed |
Competing Products
2 competing products in Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OMS302 + Phenylephrine HCl | Omeros Corporation | Phase 3 | 72 |
| SENS-111 100mg + SENS-111 200mg + Placebo Oral Tablet | Sensorion | Phase 2 | 44 |